α demonstrated considerable augmentation in both CD4 and CD8 T cell memory pool, as evidenced by significant improvement in immune response and protection against M. tb. Importantly, the vaccine showed better efficacy than BCG and hence can be a potent future vaccination strategy against TB. This evidence concerns the gene CD8A and tuberculosis.